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Abstract
Current available therapies control Myasthenia gravis (MG) reasonably well, but Health Related Quality of life
(HRQOL) remains lower than expected. The aim was provide insights in how HRQOL in MG stands across borders
and time, compare the scores to general population controls and other chronic disorders and assess the impact of
potential predictors for quality of life such as a) clinical characteristics b) antibodies c) thymoma and d) treatment in
a population-based cohort.
Methods: We designed a population-based cross-sectional study including 858 patients, 373 from Norway and 485
from the Netherlands. The Short Form Health Survey 36 (SF-36) and a cross-cultural validated questionnaire were
used. Data were in addition compared to the general population, other chronic diseases and previous studies.
Results: Mean physical composite score was 59.4 and mental composite score 69.0 with no differences between
the countries. The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001)
compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in
remission. Multivariate analysis revealed that female gender, generalized symptoms and use of secondary
immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL.
Conclusions: Remission and absence of generalized symptoms were favorable factors for HRQOL in MG patients.
Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in
this exhaustive population-based study. Further studies should explore the impact of non clinical factors like ethnic
variations, socio-economic and hormonal factors on HRQOL.
Keywords: Health-related quality of life, SF-36, Myasthenia gravis, MuSK, Seronegative MG, Acetylcholine receptor,
Thymoma, Population based, Burden of disease
Background
Myasthenia gravis (MG) is a heterogeneous neuromuscular
autoimmune disease. Clinically, the symptoms range from
mild ocular symptoms to severe generalized muscle weak-
ness and disability. In the most severe cases the respiratory
muscles are affected, causing problems breathing, a so-
called “myasthenic crisis”. Nowadays, with optimal treat-
ment, mortality is rare and most patients live normal lives.
Nevertheless, health related quality of life (HRQOL)
remains reduced compared to healthy controls in several
studies (Table 1) [1–10].
These studies show that the disease has an extensive
impact on physical, psychological and social wellbeing:
the more severe muscle symptoms and disability, the
lower the physical components of the outcome [1, 2, 7–10].
There are contradictory results as to what extend the men-
tal wellbeing is affected in MG. Reported predictors for
reduced HRQOL are among others use of prednisolone
and side-effects, disease severity, depression, anxiety and
disease duration, however, many others are also mentioned
(Table 1). There are few larger studies and the impact
of clinical subgroups based on antibodies, age of onset,
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Table 1 Overview over previous SF-36 studies amongst Myasthenia gravis patients
Author, country year Number of
patients
Design Instrument Objective Outcome compared to norm population
Paul et al., USA, 2001
[2]
27 Cohort from
Patient
organization
MGFA
SF-36 To describe HRQOL in MG patients compared to
normative data
All, except mental health and bodily pain reduced
compared to normative US population. Ratings of
mood scale within 1 SD with US norm.
Generalized
100 %
Padua et al., Italy,
2002 [1]
46 Clinical cohort SF-36 To evaluate the correlation of physician measures like
Osserman and repetitive nerve stimulation to HRQOL
outcomes
All domains largely reduced compared to normative
Italian population.
Remission: 6.5 %
Ocular: 4.3 %
Generalized: 89 %
Rostedt et al.,
Sweden, 2005-2006
[5, 6] (3 publications)
42-48 Clinical cohort SF-36 and MGQ validation To correlate MGQ, SF-36 and degree of neuromuscular
abnormalities measured by single fiber-EMG and
repetitive nerve stimulation (RNS)Remission: 20 % SF-36 and MGQ versus SF-
EMG
Ocular: 20 %
Generalized: 60 %
Leonardi et al.,
Italy, 2010 [4]
102 Clinical cohort SF-36, WHO-das II To describe HRQOL and disability profiles according to
ICF’s biopsychosocial model.
In patients without symptoms similar to general
Italian population, greater difference with more
symptoms.
Raggi et al., Italy, 2010
[3] (2 publications)
Remission: 24.5 % To verify concordance between disease’s severity,
HRQOL and disability in MG.
Ocular: 28.4 %
Generalized: 47 %
Winter et al., Germany,
2010 [7]
37 Multicenter
cohort
SF-36, EuroQoL, EQ-5D-index
score
To compare HRQOL in patients with amyotrophic
lateral sclerosis (ALS), fascial scapula humeral muscular
dystrophy (FSHD) and Myasthenia Gravis.
All domains reduced, except bodily pain compared to
normative German population
Remission: 0 % Comparison between ALS, MG
and fascial scapula humeral
muscular dystrophy.Ocular: 45.9 %
Generalized:
43.2 %
Twork et al.,
Germany, 2010 [9]
1518 Cohort from
German
Myasthenia
Associationa
SF-36 To analyze quality of life and life circumstances More than one SD from normative population data
Germany on the following domains:
Female: PF, GH
Male: PF, RP, GH, SF, RE
Female >male
Kulkantrakorn,
Thailand, 2010
[10, 29] (two
publications),
71 Clinical cohort,
two university
hospitalsa
SF-36 To study factors associated with QOL in MG patients Females lower scores than males, however P-value
is not given.
Boldingh
et
al.H
ealth
and
Q
uality
of
Life
O
utcom
es
 (2015) 13:115 
Page
2
of
14
Table 1 Overview over previous SF-36 studies amongst Myasthenia gravis patients (Continued)
Basta et al., Serbia,
2012 [8]
230 Clinical cohort SF-36, QMG, Hamilton rating,
social support
To assess factors that might influence the HRQOL in
MG patients
No population data available.
Remission: 39.1 %
Ocular: 8.7 %
Generalized:
52.2 %
Studies reporting data on only subgroups or validation studies were excluded
PF (Physical Functioning), RP (Role physical), BP (Bodily Pain), GH (General health), VT (Vitality), SF (Social Functioning), RE (Role Emotional), MH (Mental Health). Possible range 0-100; higher score indicates better
functioning. MGFA classification (Myasthenia Gravis Foundation of America). Remission (MGFA 0), ocular (MGFA 1) and generalized (MGFA 2-4)a clinical status not known. For information about the other scores or
questionnaires we refer to original publications
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thymus histology and clinical presentation remains
unanswered [11–13].
Chronic immunomodulation with corticosteroid, other
immunosuppressive drugs and thymectomy are often ne-
cessary to control the disease. Immunosuppressive medi-
cation produce marked improvement, however in many
cases does the improvement not persist if treatment is dis-
continued. Consequently, treatment in MG is often a life-
long proces [14]. The choice of treatment depends on the
severity of the symptoms, the specific subgroups and the
pace of progression [14]. It is reported that MuSK MG
and Thymoma MG are more likely to require secondary
immunosuppressives than AChR MG and that elderly are
more prone to side-effects [14–17]. As more advanced im-
munotherapy becomes available for MG patients, it is
relevant to use HRQOL as an outcome for choice of treat-
ment strategies. Long-term follow-up studies of represen-
tative MG cohorts assessing change of HRQOL during
the last decades are lacking.
Up-to-date, there is no study reflecting the HRQOL of
population-based MG cohorts covering the whole spectre
of disease activity and immunological markers. Based on
previous studies we hypothesized that serological sub-
groups, thymoma, disease course and treatment strategy
are factors affecting HRQOL in MG patients. Our aim
was to examine these factors and HRQOL in a MG cohort
as large as possible, by combining population-based MG
cohorts from two countries. We also compared the
HRQOL outcomes of the MG patients to healthy controls,
previous studies and other chronic diseases in order to get
an impression of the burden of the disease.
Methods
The design was cross sectional including two large
population based MG cohorts from the entire Norway
and a contigous province of South-Holland and North-
Holland in The Netherlands (Fig. 1). In order to in-
crease the sample size of MuSK MG in the serological
subgroup analysis, we included a national population
based sample (n = 34) from a prevalence study in the
Netherlands [18].
Study procedure
The details of the study are reported in a previous study
[19, 20]. The patients were mailed a self-administered vali-
dated questionnaire including the Short Form-36 (SF-36)
and questions about disease severity and current treat-
ment for the last three months [21]. Reminders were sent
to non-responders twice and missing data was completed
by phone or mail.
Clinical characteristics, disease onset and course, pres-
ence of antibodies and thymus histology were collected
from medical records.
Definitions
Disease course was grouped into remission; either complete
stable or pharmocological, ocular, bulbar or generalized
symptoms at the time of testing. We subgrouped the ocular
symptoms in those who started ocular and remained ocular
throughout disease course (Ocular MG) and those who
had residual ocular symptoms after generalized disease in
the MG subgroup analysis. Non-steroid immunosuppresive
medicines included azathioprine, cyclosporine, mycopheno-
late mofetil, tacrolimus, rituximab and cyclophosphamide.
Instruments
The Norwegian and Dutch translations of SF-36 (version
1) was used to assess HRQOL [22, 23] in the past four
weeks. This instrument is constructed for population
surveys, is short and easy and has good psychometric
qualities.
The SF-36 consist of 36 questions, organized into eight
domains. The eight domains are physical functioning (PF),
Role physical (problems with work or daily acitivites as a
results of physical health, RP), Bodily pain (BP), general
health evaluation (GH), Vitality (VT), Social functioning
(SF), Role emotional (RE; severe problems with work or
daily acitivites as a result of emotional health) and mental
health (MH). All items are coded, scaled and transformed
linearly from 0 (worst health) to 100 (best health). The first
four can be summarized into a physical composite score
(PCS; PF, RP, BP, GH) and the last four into a mental
summary score (MCS; VT, SF, RE, MH).
Control groups
We compared the two cohorts with published norma-
tive data, including reference data for chronic diseases
(15 different conditions) and two population-based
studies of Multiple sclerosis and Parkinsons disease
[22, 24–26].
Regulatory and ethical issues
We obtained informed constent from all participants and
approval of the regional ethical committee of South-
Norway, the ethical review committee of the Leiden
University Medical Center (LUMC), The Netherlands, and
the Medical Review Ethics Committee (METC) of South-
West Holland.
Statistical analysis
The statistical analysis was done using SPSS 22.0 (statistical
package for social sciences, IBM, Armonk, NY, USA) and
STATA 14 (StatCorp, Texas, USA). Scoring and calculation
of the SF-36 scores were done according to the improved
methods of Ware, McHorney and Sherbourne for version 1
[27, 28]. Method for impute missing data was followed for
0.7 % of the data. The MG patients were analyzed by do-
mains and composite scores. Since the composite scores
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are considered as the most robust outcome measurement
for the SF-36, we have focused on them in our compari-
sons. Differences in continuous variables were tested by
independent sample t-tests and chi-square tests for contin-
gency tables for categorical variables. When at least 25 % of
expected cell frequencies were less than 5, Fischer’s exact
test was applied. P < 0.05 was considered significant. Ad-
justment for the confounding effect of age, gender, disease
severity and differences between both countries’ samples
was done using linear regression analysis and stratum-
specific estimates. We used the population-based cohort
for all analysis (n = 837) either stratified by gender or coun-
try or pooled all together. For the immunological subgroup
analysis, we included the responders of a national sample of
MuSK MG patients (n = 21), leaving in total 856 MG
patients for the analysis since the information about
antibodies of eight patients was missing.
To examine the relationship between PCS/MCS and
the significant covariates we used multiple regression
analysis (p < 0.05) Afterwards, the model was employed
on the MG subgroups with regard to antibodies to identify
if the predictors played the same role in the subgroups.
Results
858 MG patients (72 %) of the 1189 MG patients
responded with a slightly higher response rate in Norway
(76.2 %) than in the Netherlands (68.7 %). There was no
difference considering age, sex, age onset, antibody profile
and clinical remission rate between responders and non-
responders of the questionnaire. The Dutch national sample
Fig. 1 Overview over study procedure. The study was conducted among all MG patients in Norway and the contiguous regions of
South- and North Holland in the Netherlands, including an additional MuSK Sample from entire Netherlands. The case identification
and inclusion criteria were the same in both countries. The case search in the Norwegian study area was performed nationwide
including 4 university clinics, 15 local clinics and 11 private clinics. Recruitment started: 01.01.2008. Recruitment stopped: 01.11.2009.
The case search in the Dutch study was conducted in two regions and the affiliation to the geographical area was defined by postal
code. The area had 4 university clinics, 25 local clinics and one private clinic. Recruitment started: 01.10.2011. Recruitment stopped:
01.01.2012. 43 patients were not eligible for questionnaire study because of change of address, dementia and other co-morbidities
and delay in registration of ICD-code. Abbreviations: ICD = international classification diagnosis. F: M = female: male ratio
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Table 2 Clinical characteristics of the population-based study cohort
Total cohort,
n = 837
Dutch MG Cohort,
n = 464
Norwegian
MG Cohort, n = 373
P-value Adjusted p-value
Female [n;%] 491 (58.7) 256 (55.2) 235 (63.0) 0.022 0.749
Age [mean ± SD] 60.3 (17.6) 61.2 (18)a 59.2 (17.1)a 0.099 0.215
Married /cohabiting 572 (68.3) 316 (68.1) 256 (68.6) 0.881 0.870
Single/divorced/widow 265 (31.7) 148 (31.9) 117 (31.4)
Mean age at onset [yrs ± SD] 45.8 (21.3) 49.1 (21.0) 41.8 (20.9) <0.001 <0.001
Disease duration [yrs ± SD] 12.6 (12.2) 10.7 (11.0) 15 (13.2) <0.001 <0.001
Antibody serology
AChR MG b 693 (82.2) 396 (85.3) 297 (79.6) <0.001 <0.001
MuSK MGb 20 (2.4) 18 (3.9) 2 (0.5)
SNMGb 115 (13.9) 44 (9.7) 71 (19)
Missing n = 9 (0.9 %)
Thymoma MGb 70 (21.2) 34 (25) 36 (18.8) 0.181 0.077
Age at onset [n;%]
EOMG (<50 year) 397 (47.5) 196 (42.2) 202 (54.2) <0.001 <0.001
LOMG (>50 year) 398 (47.8) 247 (53.2) 151 (47.9)
Juvenile MG (<16 years) 41 (4.9) 21 (4.5) 20 (5.4)
Disease course [n;%]
Remission 196 (23.4) 97 (20.9) 99 (26.5) <0.001 <0.001
Ocular 102 (12.2) 75 (16.2) 27 (7.2)
Bulbar 90 (10.4) 44 (9.5) 46 (12.3)
Generalized 449 (53.6) 248 (53.4) 201 (53.9)
Current treatment [n;%]:
Pyridostigmine 559 (66.8) 322 (69.4) 237 (63.5) 0.074 0.074
Prednisolone 279 (33.3) 157 (33.8) 122 (32.7) 0.731 0.966
Immunosuppressives 231 (27.6) 127 (27.4) 104 (28.0) 0.851 0.887
Combined 377 (45.0) 212 (45.7) 165 (44.0) 0.675 0.662
SF-36 [mean ± SD]
Physical functioning 64.4 (29.8) 62.2 (30.7) 67.1 (28.3) 0.017 0.014
Role Physical 51.8 (43.7) 54.5 (44.0) 48.3 (43.2) 0.041 0.035
Bodily pain 69.3 (28.0) 72.6 (26.5) 65.1 (29.4) <0.001 <0.001
General Health 52.4 (15.6) 52.7 (14.0) 52.4 (17.0) 0.802 0.896
Vitality 51.9 (22.7) 55.8 (21.3) 47.2 (23.4) <0.001 <0.001
Social functioning 72.6 (26.9) 72.4 (26.4) 73.0 (27.6) 0.754 0.64
Role Emotional 75.7 (38.6) 79.5 (36.0) 71.1 (41.3) 0.002 0.002
Mental Health 75.1 (18.1) 73.4 (18.0) 77.6 (17.7) 0.001 0.001
Physical composite score 59.4 (23.6) 60.5 (23.0) 58.4 (24.3) 0.192 0.149
Mental composite score 69.0 (21.2) 70.3 (20.5) 67.5 (22.0) 0.053 0.064
Norm-based PCS 42.4 (11.0) 42.7 (11.1) 42.0 (10.9) 0.323 0.291
Norm-based MCS 50.5 (9.4) 50.6 (9.4) 50.5 (9.4) 0.905 0.902
Abbrevations: MuSK MG presence of Muscle specific tyrosine kinase antibodies, AChR MG presence of Acetylcholine receptor antibodies, SNMG no antibodies
verified, EOMG early onset MG, LOMG late onset MG. Norm-based PCS/MCS (US norm 1998) with mean = 50 and SD =10
P-values are for difference between the Dutch and Norwegian MG cohort. Adjusted p-value for the potential confounding effect of differences in age and sex
distribution between the cohorts
ap-value < 0.005 between normative population data and study subjects
binformation derived from medical charts
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Fig. 2 HRQOL in Myasthenia Gravis compared with healthy controls. The figure illustrates the population based MG cohorts in Netherlands (a) and the
Norway (b) compared with healthy controls from their own countries. Healthy control data is provided by Loge et al.; Norway [24] and Aaronesen et al.
[22]. In summary, MG patients scored lower than healthy controls and females scored lower than males and those in remission similar to healthy controls.
The Score range from 0-100. Higher score indicate better Health related quality of life (HRQOL). Solid line is score of reference population for
men, and dotted line is score of reference population for women in their respective countries. Horizontal axes show the 8 domains of SF-
36 and composite scores
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of MuSK MG comprised more females (p = 0.011), but was
otherwise similar to the Dutch regional MuSK MG cohort.
No significant differences were found in the composite
scores of HRQOL, and only minor differences in the subdo-
mains (Table 2).
Comparison to healthy controls (Fig. 2)
The total cohort of MG patients had lower scores than
healthy controls (p-value <0.005, adjusted for age and
gender), except for the domains of bodily pain (BP) and
problems with daily activities due to mental health problems
(RE). Female MG patients systematically scored lower than
male MG patients, with significant p-values <0.001 on all
domains and composite scores (Additional file 1: Table e-1).
Patients in remission (MGFA class 0) (n = 196, 23.4 %
of the cohort) and those with ocular symptoms (MGFA
class 1) (n = 102, 12.2 %) scored similar or better than
their national normative controls on composite scores.
For both groups, the HRQOL of the domains were simi-
lar to controls, except for the domain of general health
Table 3 HRQOL results in MG subgroups
SNMG
(n = 115)
AChR MG
(n = 626)
MuSK MG
(n = 41)a
Thymoma-MG
(n = 70)
Adjusted
p-value
Female [n, %] 63 (41.4) 376 (41.3) 27 (55.1) 37 (52.9) NS
Age at study entry [yrs, SD] 54.2 (17) 61.7 (18) 52.2 (15) 61.5 (14) *b
Mean age at onset [yrs, SD] 39.5 (18) 47.1 (22) c 40.5 (17) 47.0 (17)c NS
Mean age at diagnosis [yrs, SD] 41.8 (18) 48.7 (21) c 43.1 (16) 50.4 (14.3)c NS
Disease duration [yrs, SD] 13.5 (13) 13.4 (13) 11.8 (10) 10.2 (7.9) NS
Disease course [n, %]
Remission 24 (20.9) 151 (24.1) 11 (26.2) 16 (22.9) NS
Ocular 20 (17.4) 76 (12.1) 1 (2.4) 5 (7.1) *d
Bulbar 14 (12.2) 61 (9.7) 8 (19) 12 (17.1) *d
Generalized 57 (49.6) 338 (54) 22 (52.4) 37 (52.9) NS
Current treatment [n, %]
Pyridostigmine 41 (35.7) 227 (36.3) 4 (9.5) 55 (78.6) *e
Prednisolone 25 (21.7) 205 (32.7) 21 (50) 35 (50) *f
Immunosuppressives 23 (20.2) 165 (26.6) 27 (65.7) 35 (50) *f
Combined 37 (32.5) 274 (44.1) 34 (82.9) 46 (65.7) *g
SF- 36 [mean, SD]
Physical functioning 71.3 (26.3) 62.9 (30.3) 69.3 (26.7) 65.4 (27.6) NS
Role Physical 53.8 (41.7) 51.1 (44.3) 49.4 (45.9) 55.6 (42.6) NS
Bodily pain 68.9 (28.2) 69.7 (28.1) 73.3 (24.7) 68.4 (26.3) NS
General health 52.8 (16.9) 52.6 (15.4) 51.2 (14.3) 51.4 (13.8) NS
Vitality 48.9 (21.1) 52.2 (23.2) 54.8 (20.5) 52.0 (21.2) NS
Social functioning 74.3 (26.5) 72.5 (26.9) 71.9 (27.3) 72.1 (27.6) NS
Role Emotional 79.2 (35.6) 75.4 (38.8) 82.1 (35.0) 76.2 (39.0) NS
Mental Health 74.5 (17.8) 75.6 (17.9) 69.3 (19.7) 73.7 (20.0) NS
PCS 61.7 (22.5) 59.1 (23.9) 60.8 (22.6) 60.0 (22.2) NS
MCS 69.2 (18.8) 69.0 (21.5) 69.5 (20.5) 68.5 (21.7) NS
Norm-based PCS 43.6 (11.1) 42.1 (11.1) 43.7 (10.1) 42.6 (10.2) NS
Norm-based MCS 50.2 (9.1) 50.7 (9.3) 49.2 (9.1) 49.9 (10.1) NS
Adjusted p-value is calculated with age, sex, country and antibodies as dependent variables with logistic regression analysis
Footnote aMuSk MG sample includes two MuSK MG patients from Norway, 19 MuSk patients from the study area North- and south Holland and in addition 21
from the rest of the Netherlands
*bSNMG and MuSK MG were younger than AChR MG and Thymoma MG
*cAChR MG and Thymoma MG patients were older than SNMG at onset and diagnosis
*dThere were more ocular among the SNMG and more bulbar among thymoma MG and MuSK MG
*eMuSK MG patients used less pyridostigmine than AChR MG patients (p = 0.032)
*fMuSK MG patients used more prednisolone than AChR MG (p = 0.030) and SNMG (p = 0.017) and more secondary immunosuppressives than AChR MG (p = 0.006) and
SNMG (p = 0.007)
*gBoth MuSK MG and Thymoma MG used more combination therapy with secondary immunosuppressive drugs and prednisolone than SNMG and AChR MG
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(GH), were the score was significantly worse in male
MG patients in both the Netherlands as in Norway.
MCS in particular showed age-dependent divergent re-
sults (Additional file 1: Table e-1). In the Netherlands, the
MCS was lower for those below 60 years of age; 50 % of
the females and 31 % of the males compared to controls.
In contrast, the elderly MG patients from 70 years of age
had reduced MCS in Norway compared to controls, repre-
senting 16.3 % of the females and 46 % of the males.
HRQOL in MG subgroups (Table 3, Fig. 3)
Despite different disease course and more immuno-
suppressives in MuSK MG and Thymoma MG, there
were no differences in HRQOL. No differences were
observed between early and late onset MG groups (ad-
justed for age). Patients with generalized and bulbar
symptoms had lower HRQOL scores compared to those
with OMG, residual ocular symptoms after generalized
disease and those in remission (p < 0.001). No difference
could be detected between those with OMG and those
with residual ocular symptoms after generalized disease.
No difference in PCS or MCS could be detected when
stratifying the cohort into those early MG (0-3 years
after onset) and longer follow-up (>3 years after onset).
HRQOL and treatment
Current treatment with non-steroid immunosuppressive
drugs affected PCS negatively independent of disease
Fig. 3 HRQOL by phenotype and antibodies. a MG patients in remission and absence of generalized symptoms scored significantly better than
the other groups on both composite scores (p < 0.001). b Antibody profile did not affect HRQOL outcomes
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activity (p-value <0.05 when adjusted for age, sex and
disease activity). Prednisolone alone did not lower the
PCS, but did so in combination with other immunosup-
pressive medicines (p = 0.002) . Thymectomy did not
affect HRQOL, regardless of the histology results, thym-
oma, atrophy or hyperplasia.
Correlations between SF 36 composite scores and clinical
variables
We used a multiple regression model with the PCS
and MCS as outcome variables and gender, current
disease symptoms and use of immunosuppresiva in
general (prednisolon included) as possible predictors.
Fourty-nine percent of the variance within Physical
HRQOL were explained by these markers. Together
the muscular weakness explained 44.2 % of the vari-
ance. Dyspnoe and muscular weakness in the legs
were the strongest predictors (Table 4) compared to
those without symptoms. The use of immunosup-
pressive drugs and gender were minor contributors
each explaining around 4 %, p = 0 < 0.001.
The same variables only explained 26 % of the
Mental HRQOL in MG patients. Together dyspnoe
and muscular weakness in legs, arms and neck
contributed with 35.3 % of the variance. Gender was
a minor marker, explaining around 5 %, and second-
ary immunosuppressivedrugs was not a significant
risk factors for decreased mental health (Table 5).
When applying the model on the different antibody
subgroups, the model fit better for physical than for
mental HRQOL and in particular better for MuSK MG
and Thymoma MG (Tables 4 and 5).
Comparison to other chronic diseases (Fig. 4)
We compared a stratified sample of Norwegian
MG patients with symptoms in their early disease
phase (0-3 years after onset) with patients with
Norwegian Multiple sclerosis, Parkinson’s disease
and Swedisch Rheumatoid Arthritis of similar disease
duration and mean age. MG patients scored similar
than MS patients and higher than Parkinson patients
and Rheumatoid Arthritis patients (tested by t-test).
Discussion
In this population-based double cohort study, we report
a reduced self-perceived HRQOL in Myasthenia Gravis
patients with bulbar and generalized symptoms, while
patients in remission, those with OMG and those with
residual symptoms after generalized disease scored simi-
lar to healthy controls. Generalized disease course, gen-
der, and treatment with secondary immunosuppressives
were risk factors for decreased HRQOL. Having a dis-
tinct subgroup with an antibody marker, thymoma or
early or late onset subtype did not influence the HRQOL
outcome.
The reduced quality of life was determined by lowered
physical capacities, but psychological wellbeing was af-
fected in roughly half of the patients as well. There was no
differences in HRQOL between MG patients in Norway
and the Netherlands. Pooling the data could therefore be
done without affecting the validity of the results and con-
firms the reliability of the results. Put into an historical
context, the HRQOL has not changed much for MG pa-
tients over the last 10-15 years and we found the same
levels as reported in 2001 [2, 5–10] (Fig. 5). The reduced
Table 4 Regression coefficients of physical composite score in 850 MG patients
Predictor variable Physical composite score Regression coefficient 95 % CI P-value Standard coefficient
R2 0.482
Female gender -4.69 -7.3, -2.4 <0.001 -0.102
Age -0.30 -0.3, -0.2 <0.001 -0.225
Dyspnoe -12.50 -15.3, -9.7 <0.001 -0.240
Muscular weakens in legs -12.12 -15.2, -9.4 <0.001 -0.258
Muscular weakness in neck -8.1 -11.7, -5.4 <0.001 -0.147
Muscular weakness in arms -6.7 -10.3, -4.3 <0.001 -0.149
Dysphagia -4.4 -8.4, -1.9 <0.001 -0.183
Use of immunosuppressive drugs -4.6 -6.3, -1.7 <0.001 -0.088
Model fit R2 R2 change from basis model Strongest predictors
AChR MG 0.489 7 % <0.001 Weakness legs and dyspnoe
MuSK MG 0.644 16.2 % <0.001 Weakness legs and neck
SNMG 0.484 2 % <0.001 Weakness legs and arms
Thymoma 0.588 10 % <0.001 Weakness legs and dyspnoe
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results of Padua et al. [1] may be explained by a low per-
centage in clinical remission and many patients with gen-
eralized symptoms compared to our cohort. The result of
“the more generalized disease or active” disease, the
poorer HRQOL” is in accordance with other reports [1, 3,
7, 8, 29]. Leonardi et al. [4] reported that patients in remis-
sion scored similar to Italian general population, support-
ing our findings from the Dutch and Norwegian MG
patients. We did not find any harmful impact of
antibodies or thymectomy in accordance with other
studies [1, 8, 30]. Our findings of normal levels of
HRQOL in ocular MG is supported by another study
of 91 ocular Italian MG patients [11]. In contrast, a
Japanese study reported QOL impairment of 123 ocular
MG patients in those who not responded to therapy [13].
One explanation of these contradictory results may be pa-
tients selection, since ocular MG includes several symp-
toms (ptosis, diplopia, complete ophthalmoplegia), with
potentially different grades of disability. Additionnally, the
use of another questionnaire and cultural factors may
account for the difference.
In addition to generalized weakness, dyspnoe and dys-
phagia, female gender, usage of secondary immunosup-
pressives were minor risk factors to reduced HRQOL,
similarly to results form previous studies [9, 30, 31]. Some
of the gender variability could be explained by a general
gender effect as the pattern is similar as seen in the nor-
mal population [22, 24]. However, we know that hormonal
factors affect the symptoms [32, 33] and could thus also
contribute. The second finding may suggest that long
term immunosuppressive therapy may not be as harmless
as assumed. This is supported by a HRQOL study from
Japan, which documented an impact of steroids and
calcineurin inhibitors in two studies [30, 31]. The negative
effects may be related to side-effects or to the burden of
constant need of medication. As reviewed by Sanders [14],
Table 5 Regression coefficients of mental composite score in 850 MG patients
Predictor variable Mental composite score Regression coefficient 95 % CI P-value Standard coefficient
R2 0.260
Female gender -4.8 -7.4, -2.2 <0.001 -0.111
Dyspnoe -8.6 -11.6, -5.6 <0.001 -0.143
Muscular weakness in legs -6.1 -9.2, -2.9 <0.001 -0.143
Muscular weakness in neck -10.1 -13.4, -6.8 <0.001 -0.193
Muscular weakness in arms -5.7 -8.9, -2.5 <0.001 -0.132
Age -0.13 -0.2, -0.06 <0.001 -0.113
Model fit R2 R2 change from basis model Strongest predictors
AChR MG 0.271 11 % Weakness neck
MuSK MG 0.271 11 % Weakness neck, and female gender
SNMG 0.470 21 % Weakness legs
Thymoma 0.455 19.5 % Weakness neck
Fig. 4 HRQOL in early MG patients compared to other chronic diseases. Early Norwegian Myasthenia Gravis patients from 0-3 years after onset scored
similar to MS patients [25], but better than Parkinson’s patients [26] and Rheumatoid Arthritis patients with a similar disease duration [37]
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the initial goal of therapy should be reducing weakness as
much and as quickly as possible. Balancing side effects of
immunotherapeutic agents and treatment effect remains a
challenge for the clinician. The correlation between
secondary immunosupressive agents and reduction of
HRQOL in MG patients indicates that it is import-
ant to keep in mind the benefits of usage contra the
side effects, and aim at reducing dosage to lowest
possible maintenance dose. This may in particular be
important for ocular MG in which no RCT has yet
documented effect of any secondary immunosuppres-
sive treatment, neither on symptoms remission nor
on prevention of generalized disease [34, 35].
Early MG scored similar to early MS, however
when looking at longer follow- up reports HRQOL
turns worse in MS [36]. The explanation is probably
because MS and Parkinsons’ disease have often a
more progressive course with no or less treatment
that stops progression. Rheumatoid arthritis, on the
other hand, is associated with more pain and disabil-
ity than MG which can explain the marked lower
scores. Improvement of HRQOL scores are reported
in RA within the same patients, but also improve-
ment over the last decades [37, 38]. According to
Grob et al.’s lifetime study of MG, the distribution,
severity and course of disease is determined within
the first two years [39] and many MG patients ex-
perience the worst phase of the disease in these
years. One should therefore expect improvement in
HRQOL with longer disease duration. Our study de-
sign was cross-sectional and limits therefore inter-
pretation of HRQOL over time in the same patient.
Hence, follow-up studies both of individuals over
time are needed to learn more about HRQOL in
MG. With better treatment strategies and therapau-
tic options we do also expect improvement over the
last decade, however the comparison with earlier
studies did not confirm this. Limitations in these
inter-study comparisons are that the patients are not
matched in the study and many variables are not
controlled, therefore the results are purely indicative.
The main strength of the study is the design, which is
a true population-based, cross sectional survey of two
well defined groups. Finding the same levels of HRQOL
in both countries makes the results more reliable. All
clinical subtypes of MG were present in sufficient num-
bers to give useful results. Disease specific question-
naires have been advocated for MG, and indeed may
enable a more specific follow-up for the patients [40].
Our intention was, however, to use a broadly validated
questionnaire to provide insights in how HRQOL in MG
stands across borders and time, compare the scores to
general population controls and other chronic disorders.
Correlations between the SF-36 and MG disease status
has been proven in several studies, and may thus be
trusted to give a fair picture of the burden of MG dis-
ease. A more disease specific instrument would be able
to detect smaller changes in vision, speaking, chewing
and swallowing better [1, 4–6], which was not the pur-
pose in this study. Since the SF-36 has norm-based scor-
ing, group level results of this study can be used to
compare MG patients across countries and further im-
prove the quality of health care systems in places where
it is not optimal.
Fig. 5 Overview over HRQOL measured by SF-36 from 2001-2012. Studies providing norm-based scoring are shown. Bars illustrate the distribution
of MGFA score within the cohorts, lines illustrate the PCS and MCS. Vertical axis shows SF-36 score 0-100 for lines and distribution of MGFA class
within the cohort. Padua et al. reported lower scores in 2002 than we did (p < 0.001), however the cohort consisted of fewer patients in remission
(7 %) and 89 % in MGFA class II-IV [1]. Paul et al. 2001 [2], provided not norm-based scoring, but PCS 57.6 (27) and 65.5 (24.8) were not significant
different from our study
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Conclusion
Taken together, this population based study of 857 MG
patients found the same HRQOL levels as in 2001 [2],
indicating no improvement in quality of life for MG pa-
tients despite more available immunotherapy choices
and better diagnostics of MG subgroups. Although we
included a large sample and patients with different clin-
ical characteristics, we could not find any new clinical
predictors for reduced HRQOL compared to the other
studies. Therefore we suggest that the impact of non-
clinical factors like job, socio-economic factors, physical
activity and hormonal factors on HRQOL in MG pa-
tients should be explored in order to improve the quality
of life in MG patients.
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